AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
dexbrompheniramine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 830 | 132-21-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 1.873 | Moderate | 0.79 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.346 | Moderate | 0.79 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 33.963 | 10^-6 cm/s | Moderate | 0.79 |
| dh-clint | Dog hepatocyte intrinsic clearance | 38.548 | uL/min/10^6 cells | Moderate | 0.79 |
| dppb | Dog plasma protein binding (% unbound) | 33.590 | % | Moderate | 0.79 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 45.860 | % | Moderate | 0.79 |
| herg | hERG pIC50 | 5.597 | pIC50 | Moderate | 0.79 |
| hh-clint | Human hepatocyte intrinsic clearance | 4.581 | uL/min/10^6 cells | Moderate | 0.79 |
| hlm-clint | Human liver microsomal intrinsic clearance | 13.092 | uL/min/mg protein | Moderate | 0.79 |
| hppb | Human plasma protein binding (% unbound) | 39.730 | % | Moderate | 0.79 |
| kinase-safety-class | ACVR2A,ACVR2B,AKT1,AKT2,AKT3,ALK,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK1,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PAK4,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK | 52 | |||
| kinase-selectivity-class | AKT2,AKT3,AXL,EIF2AK3,PDK4,PRKCD,STK33 | 7 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 0.459 | Moderate | 0.79 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.332 | Moderate | 0.79 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 109.144 | Moderate | 0.79 | |
| mppb | Mouse plasma protein binding (% unbound) | 32.670 | Moderate | 0.79 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.064 | Moderate | 0.79 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 49.770 | % | Moderate | 0.79 |
| rat-kpuu-brain | Rat brain Kpuu | 1.832 | % | Moderate | 0.79 |
| rh-clint | Rat hepatocyte intrinsic clearance | 97.949 | uL/min/10^6 cells | Moderate | 0.79 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 64.320 | % | Moderate | 0.79 |
| rppb | Rat plasma protein binding (% unbound) | 33.440 | % | Moderate | 0.79 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 961.612 | uM | Moderate | 0.79 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 18, 1963 | FDA | SCHERING PLOUGH |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | R06AB06 | RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Substituted alkylamines |
| ATC | R06AB56 | RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Substituted alkylamines |
| MeSH PA | D006633 | Histamine Antagonists |
| MeSH PA | D006634 | Histamine H1 Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018494 | Histamine Agents |
| CHEBI has role | CHEBI:37955 | H<small><sub>1</sub></small>-receptor antagonist |
| CHEBI has role | CHEBI:50857 | anti-allergic agent |
Related Drugs by ATC class:
R06AB Substituted alkylamines 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Dermatographic urticaria | indication | 7632005 | DOID:743 |
| Vasomotor rhinitis | indication | 8229003 | DOID:4730 |
| Allergic rhinitis | indication | 61582004 | |
| Urticaria | indication | 126485001 | |
| Influenza-like symptoms | indication | 315642008 | |
| Seasonal allergic rhinitis | indication | 367498001 | |
| Itching of skin | indication | 418363000 | |
| Allergic conjunctivitis | indication | 473460002 | DOID:11204 |
| Ocular hypertension | contraindication | 4210003 | DOID:9282 |
| Suicidal thoughts | contraindication | 6471006 | |
| Dependent drug abuse | contraindication | 6525002 | |
| Alcoholism | contraindication | 7200002 | |
| Alcohol withdrawal delirium | contraindication | 8635005 | |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Asthenia | contraindication | 13791008 | |
| Constipation | contraindication | 14760008 | DOID:2089 |
| Mood swings | contraindication | 18963009 | |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Inflammatory bowel disease | contraindication | 24526004 | DOID:0050589 |
| Ventricular tachycardia | contraindication | 25569003 | |
| Alcohol intoxication | contraindication | 25702006 | |
| Shock | contraindication | 27942005 | |
| Hypercapnia | contraindication | 29596007 | |
| Dehydration | contraindication | 34095006 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Acute hepatitis | contraindication | 37871000 | |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Disorder of gallbladder | contraindication | 39621005 | DOID:0060262 |
| Hypothyroidism | contraindication | 40930008 | DOID:1459 |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Low blood pressure | contraindication | 45007003 | |
| Chronic heart failure | contraindication | 48447003 | |
| Bradycardia | contraindication | 48867003 | |
| Acidosis | contraindication | 51387008 | |
| Coronary arteriosclerosis | contraindication | 53741008 | DOID:3393 |
| Hepatic failure | contraindication | 59927004 | |
| Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
| Arterial thrombosis | contraindication | 65198009 | |
| Substance abuse | contraindication | 66214007 | |
| Benign intracranial hypertension | contraindication | 68267002 | DOID:11459 |
| Poisoning by acetaminophen | contraindication | 70273001 | |
| Arteriosclerotic vascular disease | contraindication | 72092001 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Urethral stricture | contraindication | 76618002 | |
| Decreased respiratory function | contraindication | 80954004 | |
| Injury of head | contraindication | 82271004 | |
| Chronic idiopathic constipation | contraindication | 82934008 | |
| Cor pulmonale | contraindication | 83291003 | DOID:8515 |
| Pulmonary emphysema | contraindication | 87433001 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Acute abdominal pain | contraindication | 116290004 | |
| Neoplasm of brain | contraindication | 126952004 | DOID:1319 |
| Seizure disorder | contraindication | 128613002 | |
| Drug-induced psychosis | contraindication | 191483003 | DOID:1742 |
| Partial atrioventricular block | contraindication | 195039008 | |
| Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Bladder outflow obstruction | contraindication | 236645006 | |
| Morbid obesity | contraindication | 238136002 | DOID:11981 |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Retention of urine | contraindication | 267064002 | |
| Exacerbation of asthma | contraindication | 281239006 | |
| Lesion of brain | contraindication | 301766008 | |
| Coma | contraindication | 371632003 | |
| Primary adrenocortical insufficiency | contraindication | 373662000 | |
| Operation on gastrointestinal tract | contraindication | 386621005 | |
| Hypoxia | contraindication | 389086002 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Disorder of coronary artery | contraindication | 414024009 | |
| Central nervous system depression | contraindication | 418072004 | |
| Dysfunction of sphincter of Oddi | contraindication | 430887001 | |
| Hypertensive urgency | contraindication | 443482000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.47 | Basic |
| pKa2 | 4.14 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Histamine H1 receptor | GPCR | ANTAGONIST | DRUGBANK | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019711 | VUID |
| N0000147803 | NUI |
| D03704 | KEGG_DRUG |
| 2391-03-9 | SECONDARY_CAS_RN |
| 22696 | RXNORM |
| 4018841 | VANDF |
| 4019711 | VANDF |
| C0057605 | UMLSCUI |
| CHEBI:59269 | CHEBI |
| CHEMBL1201287 | ChEMBL_ID |
| CHEMBL1200638 | ChEMBL_ID |
| DB00405 | DRUGBANK_ID |
| C015121 | MESH_SUPPLEMENTAL_RECORD_UI |
| 16960 | PUBCHEM_CID |
| 7588 | IUPHAR_LIGAND_ID |
| 907 | INN_ID |
| 75T64B71RP | UNII |
| 4555 | MMSL |
| d03750 | MMSL |
| 003411 | NDDF |
| 004436 | NDDF |
| 387090008 | SNOMEDCT_US |
| 387429005 | SNOMEDCT_US |
| 75429004 | SNOMEDCT_US |
| 75T64B71RP | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Dexbrompherniramine Maleate and Pseudoephedrine Sulfate6mg/120mg | HUMAN OTC DRUG LABEL | 2 | 10702-005 | TABLET, EXTENDED RELEASE | 6 mg | ORAL | ANDA | 13 sections |
| Chlo Tuss | HUMAN OTC DRUG LABEL | 3 | 12830-762 | LIQUID | 1 mg | ORAL | OTC Monograph Drug | 16 sections |
| Chlo Tuss | HUMAN OTC DRUG LABEL | 3 | 12830-762 | LIQUID | 1 mg | ORAL | OTC Monograph Drug | 16 sections |
| M-ENDDMX | HUMAN OTC DRUG LABEL | 3 | 12830-816 | LIQUID | 0.67 mg | ORAL | OTC Monograph Drug | 16 sections |
| M-ENDDMX | HUMAN OTC DRUG LABEL | 3 | 12830-816 | LIQUID | 0.67 mg | ORAL | OTC Monograph Drug | 16 sections |
| Chlo Hist | HUMAN OTC DRUG LABEL | 2 | 12830-864 | LIQUID | 1 mg | ORAL | OTC Monograph Drug | 15 sections |
| Chlo Hist | HUMAN OTC DRUG LABEL | 2 | 12830-864 | LIQUID | 1 mg | ORAL | OTC Monograph Drug | 15 sections |
| G-Con-X | HUMAN OTC DRUG LABEL | 2 | 43913-405 | LIQUID | 1 mg | ORAL | OTC MONOGRAPH FINAL | 15 sections |
| BionatussDXP | HUMAN OTC DRUG LABEL | 3 | 45737-210 | LIQUID | 2 mg | ORAL | OTC Monograph Drug | 10 sections |
| BIO-CNEX | HUMAN OTC DRUG LABEL | 2 | 45737-239 | LIQUID | 1 mg | ORAL | OTC Monograph Drug | 9 sections |
| Biogesic | HUMAN OTC DRUG LABEL | 2 | 45737-610 | TABLET | 1 mg | ORAL | OTC Monograph Drug | 9 sections |
| Chlo Hist | HUMAN OTC DRUG LABEL | 2 | 50090-3998 | LIQUID | 1 mg | ORAL | OTC monograph final | 15 sections |
| DURATUSSDM | HUMAN OTC DRUG LABEL | 3 | 50991-142 | LIQUID | 1 mg | ORAL | OTC Monograph Drug | 16 sections |
| Duratuss AC | HUMAN OTC DRUG LABEL | 2 | 50991-540 | LIQUID | 1 mg | ORAL | OTC Monograph Drug | 14 sections |
| ALA-HIST IR | HUMAN OTC DRUG LABEL | 1 | 50991-783 | TABLET | 2 mg | ORAL | OTC Monograph Drug | 13 sections |
| Alahist CF | HUMAN OTC DRUG LABEL | 3 | 50991-784 | TABLET | 2 g | ORAL | OTC monograph final | 10 sections |
| Alahist PE | HUMAN OTC DRUG LABEL | 2 | 50991-788 | TABLET | 2 mg | ORAL | OTC Monograph Drug | 15 sections |
| Durahist | HUMAN OTC DRUG LABEL | 2 | 50991-865 | TABLET | 2 mg | ORAL | OTC Monograph Drug | 16 sections |
| SUPRESS A | HUMAN OTC DRUG LABEL | 3 | 52083-057 | SYRUP | 1 mg | ORAL | OTC monograph final | 14 sections |
| SUPRESS A | HUMAN OTC DRUG LABEL | 3 | 52083-057 | SYRUP | 1 mg | ORAL | OTC monograph final | 14 sections |
| Dologen | HUMAN OTC DRUG LABEL | 2 | 52083-481 | TABLET | 2 mg | ORAL | OTC monograph final | 10 sections |
| Dologen 325 | HUMAN OTC DRUG LABEL | 2 | 52083-482 | TABLET | 1 mg | ORAL | OTC monograph final | 10 sections |
| DOLOGEN | HUMAN OTC DRUG LABEL | 2 | 52083-483 | TABLET | 2 mg | ORAL | OTC Monograph Drug | 11 sections |
| G-Dologen | HUMAN OTC DRUG LABEL | 2 | 52083-681 | TABLET | 2 mg | ORAL | OTC monograph final | 10 sections |
| G-DOLOGEN | HUMAN OTC DRUG LABEL | 2 | 52083-683 | TABLET | 2 mg | ORAL | OTC Monograph Drug | 11 sections |
| DologesicNF | HUMAN OTC DRUG LABEL | 2 | 54859-001 | TABLET | 1 mg | ORAL | OTC Monograph Drug | 10 sections |
| DologesicDF | HUMAN OTC DRUG LABEL | 2 | 54859-010 | TABLET | 1 mg | ORAL | OTC Monograph Drug | 10 sections |
| Conex | HUMAN OTC DRUG LABEL | 2 | 54859-702 | TABLET | 2 mg | ORAL | OTC Monograph Drug | 12 sections |
| Conex | HUMAN OTC DRUG LABEL | 2 | 54859-802 | LIQUID | 1 mg | ORAL | OTC Monograph Drug | 10 sections |
| Conex Pediatric | HUMAN OTC DRUG LABEL | 2 | 54859-803 | LIQUID | 1 mg | ORAL | OTC Monograph Drug | 10 sections |